A multifaceted therapy that blocks multiple pathways—such as osimertinib plus an AXL inhibitor (ONO-7475) and an FGFR inhibitor (BGJ398)—has demonstrated marked antitumor effects in high-AXL-expressing, EGFR-mutant NSCLC cells [168,170,184]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.